Alto Neuroscience, Inc. (ANRO)
After hours:
| Previous close | 11.81 |
| Open | 11.91 |
| Bid | 12.24 x 900 |
| Ask | 19.41 x 1200 |
| Day's range | 11.71 - 12.45 |
| 52-week range | 10.85 - 24.00 |
| Volume | |
| Avg. volume | 147,257 |
| Market cap | 334.437M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
LOS ALTOS, Calif., May 29, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced that Company management will participate in the Jefferies Global Healthcare Conference, taking place June 5-6, 2024, in New York. Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in a fireside chat on Thursday, June 6, 2024, at 2:30 p.m. ET, and management will host one-on-one meetings with investors.
- Business Wire
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
LOS ALTOS, Calif., May 21, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. A
- Business Wire
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
LOS ALTOS, Calif., May 14, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
